NCT02327078 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 83
- group Id
- BG008
- value
- 176
- group Id
- BG009
- value
- 307
- units
- Participants
- groups
- description
- Participants received epacadostat 25 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG000
- title
- Phase 1, Part 1: Epacadostat 25 mg + Nivolumab 3 mg
- description
- Participants received epacadostat 50 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG001
- title
- Phase 1, Part 1: Epacadostat 50 mg + Nivolumab 3 mg
- description
- Participants received epacadostat 100 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG002
- title
- Phase 1, Part 1: Epacadostat 100 mg + Nivolumab 3 mg
- description
- Participants received epacadostat 300 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG003
- title
- Phase 1, Part 1: Epacadostat 300 mg + Nivolumab 3 mg
- description
- Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with 5-FU/Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.
- id
- BG004
- title
- Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + 5-FU/Platinum
- description
- Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with Pemetrexed /Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.
- id
- BG005
- title
- Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + Pemetrexed/ Platinum
- description
- Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with Paclitaxel/Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.
- id
- BG006
- title
- Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + Paclitaxel/ Platinum
- description
- Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 and participants with melanoma I/O-relapsed and melanoma I/O-refractory enrolled in this arm received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q4W on Days 1 and Day 29 of each 8-week cycle.
- id
- BG007
- title
- Phase 2: Epacadostat 100 mg + Nivolumab 240/480 mg
- description
- Participants with select solid tumor types received epacadostat 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG008
- title
- Phase 2: Epacadostat 300 mg + Nivolumab 240 mg
- description
- Total of all reporting groups
- id
- BG009
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 26.00
- value
- 50.0
- group Id
- BG001
- spread
- 12.41
- value
- 62.5
- group Id
- BG002
- spread
- 13.27
- value
- 57.5
- group Id
- BG003
- spread
- 10.67
- value
- 61.6
- group Id
- BG004
- spread
- 6.38
- value
- 64.3
- group Id
- BG005
- spread
- 6.43
- value
- 67.7
- group Id
- BG006
- spread
- 11.37
- value
- 70.3
- group Id
- BG007
- spread
- 13.82
- value
- 56.7
- group Id
- BG008
- spread
- 12.12
- value
- 62.6
- group Id
- BG009
- spread
- 12.33
- value
- 60.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 46
- group Id
- BG008
- value
- 77
- group Id
- BG009
- value
- 145
- title
- Female
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 37
- group Id
- BG008
- value
- 99
- group Id
- BG009
- value
- 162
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 6
- group Id
- BG008
- value
- 11
- group Id
- BG009
- value
- 17
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 77
- group Id
- BG008
- value
- 159
- group Id
- BG009
- value
- 283
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 3
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 7
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 76
- group Id
- BG008
- value
- 160
- group Id
- BG009
- value
- 282
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 8
- group Id
- BG009
- value
- 14
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- The safety population included all participants enrolled in the study who received at least 1 dose of epacadostat, nivolumab, or an applicable chemotherapy regimen.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 83
- group Id
- BG008
- value
- 176
- group Id
- BG009
- value
- 307
- units
- Participants
- groups
- description
- Participants received epacadostat 25 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG000
- title
- Phase 1, Part 1: Epacadostat 25 mg + Nivolumab 3 mg
- description
- Participants received epacadostat 50 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG001
- title
- Phase 1, Part 1: Epacadostat 50 mg + Nivolumab 3 mg
- description
- Participants received epacadostat 100 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG002
- title
- Phase 1, Part 1: Epacadostat 100 mg + Nivolumab 3 mg
- description
- Participants received epacadostat 300 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG003
- title
- Phase 1, Part 1: Epacadostat 300 mg + Nivolumab 3 mg
- description
- Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with 5-FU/Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.
- id
- BG004
- title
- Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + 5-FU/Platinum
- description
- Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with Pemetrexed /Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.
- id
- BG005
- title
- Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + Pemetrexed/ Platinum
- description
- Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 360 mg, IV, Q2W, on Day 1 of each 21-day cycle along with Paclitaxel/Platinum chemotherapy regimen IV. Participants were de-escalated to epacadostat 50 mg BID if 100 mg was not tolerated.
- id
- BG006
- title
- Phase 1, Part 2: Epacadostat 100 mg + Nivolumab 360 mg + Paclitaxel/ Platinum
- description
- Participants with select solid tumor types received epacadostat 100 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 and participants with melanoma I/O-relapsed and melanoma I/O-refractory enrolled in this arm received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q4W on Days 1 and Day 29 of each 8-week cycle.
- id
- BG007
- title
- Phase 2: Epacadostat 100 mg + Nivolumab 240/480 mg
- description
- Participants with select solid tumor types received epacadostat 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.
- id
- BG008
- title
- Phase 2: Epacadostat 300 mg + Nivolumab 240 mg
- description
- Total of all reporting groups
- id
- BG009
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 26.00
- value
- 50.0
- group Id
- BG001
- spread
- 12.41
- value
- 62.5
- group Id
- BG002
- spread
- 13.27
- value
- 57.5
- group Id
- BG003
- spread
- 10.67
- value
- 61.6
- group Id
- BG004
- spread
- 6.38
- value
- 64.3
- group Id
- BG005
- spread
- 6.43
- value
- 67.7
- group Id
- BG006
- spread
- 11.37
- value
- 70.3
- group Id
- BG007
- spread
- 13.82
- value
- 56.7
- group Id
- BG008
- spread
- 12.12
- value
- 62.6
- group Id
- BG009
- spread
- 12.33
- value
- 60.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 46
- group Id
- BG008
- value
- 77
- group Id
- BG009
- value
- 145
- title
- Female
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 37
- group Id
- BG008
- value
- 99
- group Id
- BG009
- value
- 162
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 6
- group Id
- BG008
- value
- 11
- group Id
- BG009
- value
- 17
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 77
- group Id
- BG008
- value
- 159
- group Id
- BG009
- value
- 283
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 3
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 7
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 76
- group Id
- BG008
- value
- 160
- group Id
- BG009
- value
- 282
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 8
- group Id
- BG009
- value
- 14
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- The safety population included all participants enrolled in the study who received at least 1 dose of epacadostat, nivolumab, or an applicable chemotherapy regimen.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle